Richard Lafayette, MD
Enriched profileProfessor of Medicine (Nephrology) · Stanford University School of Medicine
Richard Lafayette is Professor of Medicine (Nephrology) at Stanford University School of Medicine. OpenAlex indexes 306 publications with 10,765 citations (h-index 51); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Richard A. Lafayette, MD, is Professor of Medicine (Nephrology) at Stanford University School of Medicine. The public record shows 306 publications with 10,765 citations (h-index 51), centered on Nephrology. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 23 companies, 1 NIH-funded awards (2000–2001).
- Most recent indexed publication: 2026 · Clinical journal of the American Society of Nephrology
- Top research focus: Nephrology
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Research focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Sponsor: Stanford University
Industry payments
Updated 27 Aug 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202520 payments$30,404openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year202517 payments$20,055openpaymentsdata.cms.gov ↗
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year202516 payments$19,477openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.6%Calcium channel blocker14.3%Amlodipine Besylate89%Nifedipine Er11%Part D<11 patientsStatin12.7%Atorvastatin Calcium67%Rosuvastatin Calcium18%Simvastatin15%Part D<11 patientsMetabolism & gastrointestinal
13.7%Corticosteroid4.2%Prednisone100%Part D<11 patientsSGLT2 inhibitor3.6%Farxiga73%Jardiance28%Part D<11 patientsNervous system
6%Benzodiazepine2%Lorazepam100%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator1.7%Zolpidem Tartrate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
1 NIH research award on record, funded 2000–2001 per NIH RePORTER. The latest:
- ORAL CALCIMIMETIC AGENT IN SECONDARY HYPERPARATHYROIDISM
Stanford University
FY2001$134,676M01RR000070
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.
Clinical journal of the American Society of Nephrology
Article2026 - A plain language summary: long-term safety and effectiveness of atacicept in individuals with IgA nephropathy.
Current medical research and opinion
Article2025 - TESTING for the Best Biomarker in IgA Nephropathy.
Clinical journal of the American Society of Nephrology
Article2025 - Authors' Reply: Ravulizumab in IgA Nephropathy: A Promising Step Toward Disease Modification?
Journal of the American Society of Nephrology
Article2025 - Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations.
Advances in therapy
Article2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/richard-lafayette-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
medicine.stanford.edu/news/current-news/standard-news/lafayette-named-chief-editor.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.stanford.edu ↗ - X / Twitter
x.com/asnkidney
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.stanford.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Founder and Director
Stanford Glomerular Disease Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Media & interviews
press, podcasts and appearances- ASN Podcast: "Kidney Week 2025 - Late-Breaking Clinical Trials" panel with Julie R. Ingelfinger
MD and Hiddo Jan L. Heerspink, PhD …
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →threads.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Mark Pegram, MD
Stanford University School of Medicine
Vibeke Strand, MD
Stanford University School of Medicine